Every year, more than 1 million patients in the U.S. find themselves suffering from respiratory complications following surgery, according to Hill-Rom (NYSE:HRC).
These complications come at a cost – to both the patient and the hospital. A respiratory problem can increase a patient’s time in the hospital by as much as 89%. More people die each year from pulmonary complications than from breast cancer, the Chicago-based company reported.
To stop these complications from ever developing, Hill-Rom has developed the MetaNeb System, which combines secretion mobilization, lung expansion therapy and aerosol delivery. Drug Delivery Business News editor Sarah Faulkner spoke with Dr. Carlos Urrea, Hill-Rom’s VP of medical affairs, about the needs that motivated MetaNeb’s design and the patient outcomes linked to the device’s use.
See the best minds in medtech live at DeviceTalks Boston on Oct. 2.
